Nevertheless, our observations suggest that when poly(I:C) is selected as a therapeutic vaccine for cervical cancer, special attention should be paid to its effect on the local microenvironment of the tumour, and relevant measures should be taken to inhibit its promotion of IL‐6 secretion. The gene discussed is IL6; the disease is cervical carcinoma.